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The authors report a case of primary rhabdomyosarcoma of the diaphragm, an extremely rare presentation with only 14 cases
reported in the literature.
An 18-year-old male presented 2 spontaneous occurrences of pneumothorax. Computed tomography and magnetic resonance
showed a tumoral mass on the right diaphragmatic surface, and after biopsy, the diagnosis was compatible with spindle cell
rhabdomyosarcoma. Because the visceral pleura was invaded by the tumoral mass, a right pleuropneumonectomy was performed.
The patient received adjuvant chemotherapy, and there was no evidence of disease 15 months after the operation.
Based on the Intergroup Rhabdomyosarcoma Study Group (IRSG) criteria, which consider the extent of the disease and its
surgical resectability, rhabdomyosarcomas can be classified into 4 groups. In clinical group I, which was the classification of our
patient, the tumor is localized and completely resectable, which implies a good prognosis. Rhabdomyosarcoma is a rare tumor, and
a good outcome may result if it is completely resected.
DESCRIPTORS: Rhabdomyosarcoma. Sarcoma. Diaphragm. Embryonal. Adolescent.
Rhabdomyosarcoma (RMS) is a
malignant tumor arising in skeletal
muscle, and it is the most common
soft-tissue sarcoma in children and
adolescents, accounting for 15% of
soft-tissue sarcomas in the general
population and 4% to 8% of all child-
hood malignancies1.
There are 4 histologic subtypes of
RMS: pleomorphic, alveolar, botryoid,
and embryonal, the latter being the
most frequently occurring soft-tissue
sarcoma in childhood. The head and
neck region and urogenital tract are
most common sites of presentation1-3.
The embyonal tumor is occasionally
found in adults and the elderly. Primary
rhabdomyosarcomas of the diaphragm
are extremely rare tumors, with only 14
cases reported in the literature.
We present a case of diaphragmatic
spindle cell embryonal rhabdomyosa-
rcoma in a young male.
CASE REPORT
An 18-year-old male presented
with dyspnea and ventilatory-depend-
ent pain at the posterior region of the
right hemithorax. He had experienced
2 spontaneous occurrences of pneu-
mothorax, and during the second one
(one year before admission to our de-
partment) a thoracotomy with biopsy
and pneumothorax drainage were per-
formed. Histologic examination was
negative for malignancy. Physical ex-
amination showed reduced breath
sounds at the right hemithorax.
CT scan (Fig. 1) demonstrated the
presence of a 5-cm solid mass on the
right pleural surface, extending to the
right posterior mediastinum. He under-
went videothoracoscopy with biopsy;
microscopic exam revealed a spindle
cell embryonal RMS, and immunohis-
tochemical findings confirmed it.
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Magnetic resonance (Fig. 2)
showed an extensive lesion, with the
largest diameter of 5 cm, at the base of
the right hemithorax compressing the
hepatic surface and extending to the
right mediastinum.
Eleven months after surgery, a rou-
tine CT scan showed a probable recur-
rence of the tumor on the diaphragm.
The patient underwent another thora-
cotomy revealing only a hematoma in
the thoracic wall and intense local fi-
brosis. Resection of the hematoma and
curettage of the thoracic wall were per-
formed. Microscopic evaluation did not
show recurrent disease.
At the follow-up evaluation 15
months after surgery, no evidence of
disease was found.
DISCUSSION
Rhabdomyosarcoma (RMS) is the
most frequently occurring soft tissue
sarcoma in children and young adults
and has been divided into 4 histologic
subtypes: embryonal (58%), botryoid
(subtype of embryonal, corresponding
to 10 percent of RMSs), alveolar
(14%), and pleomorphic (16%)3,4.
Rhabdomyosarcoma may occur at
any site, but primary tumors are more
commonly located in head and neck
(42%), urogenital tract (34%), and ex-
tremities (11%)3. Alveolar tumors tend
to occur primarily in trunk and ex-
tremities, whereas embryonal tumors
are more often found in the head and
neck or genitourinary and parates-
ticular sites5.
Primary tumors of the diaphragm
are uncommon entities, and diaphrag-
matic rhabdomyosarcoma is an ex-
tremely rare tumor6. Table 1 shows all
14 cases of primary RMSs of the dia-
phragm that have been reported since
1939.
In general, diaphragmatic tumors,
either benign or malignant, do not ex-
press any symptom at the onset10. Our
patient experienced 2 spontaneous oc-
currences of pneumothorax, which
led us to start an investigation.
In contrast to the pediatric popula-
tion, RMS in adults is comparatively
rare, with the alveolar subtype pre-
dominating in adult patients 25 years
of age or less, and the pleomorphic
subtype predominating in adult patients
over the age of 2512.
Somatically acquired mutations un-
derlie all forms of human cancer, but
until recently, little was known about
those associated with rhabdomyosar-
coma. Cytogenetic and molecular ge-
netic studies have identified both nu-
Table 1 - Primary rhabdomyosarcoma of the
diaphragm.
Author Year Number
of cases
Ryan7 1939 1
Peery & Smith7 1939 1
Weiner & Chow6 1965 2
Olafasson et al.6 1971 2
Hein6 1974 1
Federici et al.6 1985 1
Federici et al.8 1986 1
Vaño et al.9 1988 1
Rea et al.6 1992 1
Eustace S & Fitzgerald7 1993 1
Midorikawa et al.10 1998 1
Gupta et al.11 1999 1
TOTAL 14
Figure 1 - CT scan showing a mass in right
hemithorax.
Figure 2 - Magnetic resonance showing a mass
in right hemithorax.
Figures 3a and 3b - Tumor tissue with bundles
of primitive mesangial cells similar to myoblasts.
Spindle-shaped cells with eosinophilic
cytoplasm and elongated nuclei with dense
chromatin (HEx40 e HEx100).
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During right thoracotomy, a dia-
phragmatic mass was identified, and
multiple contiguous implants in the
visceral and parietal pleura were no-
ticed. Because of the extent of the le-
sion, a right pleuropneumonectomy
and partial resection of diaphragmatic
muscle with primary suture was per-
formed. Histologic examination (Figs.
3a and 3b) revealed a poorly differen-
tiated spindle cell sarcoma, compatible
with spindle cell embryonal rhabdomy-
osarcoma, without nodal metastasis in
the mediastinum.
The postoperative course was un-
eventful, and the patient was dis-
charged from the hospital on the ninth
postoperative day. Adjuvant chemo-
therapy with doxorubicin, ifosfamide,
and dacarbazine was initiated.
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merical and structural abnormalities of
tumor-cell chromosomes. Recurrent
chromosomal translocations, including
t(2;13)(q35;q14) and less commonly
t(1;13)(p36;q14), have been identified
in most cases of alveolar rhabdomy-
osarcoma13-15. The t(2;13) translocation
results in fusion of part of the PAX3
gene to part of the FKHR gene, lead-
ing to formation of the PAX3-FKHR
gene that encodes a chimeric protein.
In case of t(1;13) translocation, the
PAX7-FKHR gene is formed14-16. The
chimeric transcript may be detected by
reverse transcription followed by
polymerase chain reaction (PCR)17.
Studies have suggested that clinical
features, natural history of disease, and
response to therapy differ in subgroups
of patients according to the presence of
t(2;13) or t(1;13) translocation or the
absence of both translocations15.
Some gene alterations other than
PAX3/7-FKHR fusion might be mark-
ers of aggressiveness of RMSs. Altera-
tions of the tumor suppressor p53 gene
are the most frequent gene alterations
in human cancer. These alterations are
related to poor prognosis in several
cancers including soft-tissue sarcomas
in adults18.
Cytogenetic and molecular abnor-
malities related to embryonal RMSs
include hyperdiploidy19, trisomy of
chromosomes 2, 13, and 1820, and loss
of heterozygosity for polymorphic
markers at 11p15.5 and 16q20. Other
mutations or amplifications of tumor-
suppressor genes, oncogenes, or tumor-
specific fusion genes (e.g., p53, N-ras,
K-ras and N-myc) are frequently ob-
served and may be involved in the
pathogenesis of rhabdomyosarcoma or
may represent secondary events related
to progression of the tumor13,20.
The Intergroup Rhabdomyosar-
coma Study Group (IRSG) is the ma-
jor worldwide protocol study group of
rhabdomyosarcomas, and since 1972,
has been conducting sequential pro-
spective studies of these tumors. By
1998, these studies had included more
than 3000 children, which comprised
about three-fourths of all patients in
North America21. According to the
IRSG, rhabdomyosarcomas are divided
into 4 surgical-histopathologic groups,
based on the extent of disease, surgi-
cal decision, and extent of resection
(Table 2)1. The international literature
has been using this classification sys-
tem for establishment of treatment and
prognosis for patients with RMS1,2.
In all intergroup rhabdomyosar-
coma studies (IRS), patients were
randomized or assigned to therapy ac-
cording to clinical group and received
chemotherapy associated or not with
radiotherapy (RT) after surgery. There-
fore, prognostic factors and indications
for RT and chemotherapy for different
subtypes of RMS could be defined. In
both IRS-I and IRS-II, survival at 5
years decreased from approximately
82% in patients with localized tumors
that could be removed by surgery
(clinical group I) to approximately
24% in patients with metastatic disease
(clinical group IV). These results em-
phasize the crucial role of disease ex-
tent (i.e., clinical group) in predicting
survival1.
For patients with group I embryo-
nal tumors, primary tumor location was
strongly associated with outcome. Pa-
tients with tumors arising in
genitourinary and paratesticular loca-
tions had a good prognosis1,5, whereas
patients with disease in the extremities
had relatively poor survival1. No differ-
ences at outcome were observed when
considering age, sex, study, or whether
or not the patient received RT5. In IRS-
I, patients with tumors larger than 5 cm
in diameter had the poorest survival
experience; tumor size was not related
to survival in IRS-II1. Considering only
histology and survival, patients with
alveolar tumors fared the worst (5-year
survival, 47% in IRS-I and 57% in
IRS-II), whereas patients with botryoid
or embryonal tumors had the best sur-
vival (95% and 92%, respectively)1.
Estimated 10-year failure-free survival
for patients with group I embryonal
RMS was 92% in IRS-I and 81% in
IRS-II5. The effect of RT on outcome
was analyzed according to tumor his-
tology for patients treated on IRS-I, II,
and III, and no benefit was found for
patients with group I embryonal RMS5.
The patient in our study presented
a mass on right diaphragm with con-
tiguous implants in the parietal and vis-
ceral pleura. He underwent right
pleuropneumonectomy with partial re-
section of the diaphragm. The decision
was made to perform right lung resec-
tion because of the impairment of the
visceral pleura. Using the IRSG crite-
ria, this patient was classified as group
I, since this group includes patients
with complete tumoral resection with-
out clinical and/or radiographic evi-
dence of distant or nodal metastases.
His histologic subtype (embryonal)
and his clinical group are predictors of
good prognosis. However, the size of
tumor and its location were indicators
of poor outcome.
The American Joint Committee for
Cancer Staging (AJCC) system can
also be used for staging patients with
RMS and relies on histologic grade
(G), tumor size (T), nodal status (N),
and the presence or absence of distant
metastases (M)22. According to this
system, the patient would be classified
as stage III. Nevertheless, the IRSG
Table 2 - IRSG surgical-pathologic
grouping system2.
Group I Localized disease, completely
resected
Group II Microscopic disease remaining
with or without completely
resected regional nodal disease
Group III Incomplete resection or biopsy
with gross residual disease
Group IV Distant metastases present at
onset
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staging system was used, since this
group studies only rhabdomyosarcoma
and this classification system is specific
for this kind of tumor.
For unresectable local or regional
tumors in less favorable sites, radiation
therapy is recommended early in the
course of treatment21. Radiation
therapy was not performed because our
patient did not fit in these criteria.
Neoadjuvant chemotherapy was not
used because IRSG protocols still had
not established the role of this thera-
peutic modality when our patient was
treated; until IRS-III was completed,
no protocol recommended neoadjuvant
chemotherapy as the gold standard.
The classification of our patient
into group I was based in the absence
of compromised surgical margins in
the resected mass; nevertheless, due to
the size of the tumor, classification into
group II cannot be totally excluded.
However, this change in clinical group
would not change the adjuvant treat-
ment administered. Although IRS-IV
recommends RT with 4100 cGy at
week 9 (day 62) after surgery for group
II patients, our patient could not re-
ceive this therapeutic regimen because
a right deviation of the mediastinum
had occurred. Because of the size of
the tumor, we would have had to irra-
diate the entire right hemithorax from
the diaphragmatic surface to the upper
lobe of the lung. This irradiation would
probably had affected the contralateral
lung, the heart, and other deviated
structures of the mediastinum in higher
doses than these organs can tolerate.
We should also note that until IRS-IV
was completed in 2000 (and which was
ongoing at the time our patient was be-
ing treated), IRSG protocols did not
show a benefit from using postopera-
tive RT with patients with group I
tumors. Nowadays, it is believed that
radiation therapy may benefit group I
patients who have a less favorable
prognosis (e.g., alveolar histology)23.
For patients with embryonal rhab-
domyosarcoma in a site associated with
a favorable outcome (i.e., the head and
neck, but not the parameningeal area
and the entire genitourinary tract except
for the bladder and prostate) who have
undergone complete or nearly complete
resection (with only microscopic re-
sidual tumor), treatment with VA (vin-
cristine and dactinomycin) is indicated
according to IRSG protocols21,24. How-
ever, patients with alveolar tumors re-
quire the addition of cyclophosphamide
to the regimen. The cure rate among
such low-risk patients is 90 to 95 per-
cent, and about one-third of patients
with newly diagnosed rhabdomyosar-
coma belong to this low-risk group13,16.
Patients with all types of gross residual
tumor, except orbital tumors, are consid-
ered to be at intermediate risk, with a
cure rate of 70 to 80 percent, requiring
more intensive chemotherapy that in-
cludes at least 3 drugs (vincristine,
dactinomycin, and cyclophospha-
mide)13,16. The fourth IRS compared
VAC (vincristine, dactinomycin, and cy-
clophosphamide), VAI (vincristine,
dactinomycin, and ifosfamide) and VIE
(vincristine, ifosfamide, and etoposide)
regimens and demonstrated no advan-
tage in substituting cyclophosphamide
for ifosfamide or dactinomycin for
etoposide in the 3-drug chemotherapy
regimen25. The fifth IRS is exploring use
of these 3 drugs plus topotecan, the pio-
neer of the new class of anticancer
agents, topoisomerase I inhibitors. The
overall response to topotecan was 46%
in patients with metastatic disease, and
the response was better in alveolar
tumors (65%) than in embryonal tumors
(28%)26.
Our patient received MAID (mesna,
doxorubicin, ifosfamide, and dacar-
bazine) chemotherapy postoperatively,
which is the first choice for sarcoma be-
cause it includes the two most effective
drugs against this tumor (ifosfamide and
doxorubicin)27. In spite of good re-
sponses of this combination, sometimes
VAC may replace MAID regimen, as
observed in IRSG protocols. Although
less effective, the VAC regimen does not
cause heart toxicity induced by
doxorubicin.
Rhabdomyosarcoma is a malignant
tumor that can arise at any site of the
organism. Signs and symptoms depend
on the anatomic site of the tumor, and
prognosis varies according to tumor
size, histology, localization, clinical
group, and cytogenetic alterations. Bet-
ter supportive care and systematic appli-
cation of increasingly effective
multimodal treatment have dramatically
improved survival over this period, with
5-year survival rates rising from ap-
proximately 10 to 20 percent in 1970 to
about 60 to 70 percent currently.
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RESUMO RHCFAP/3071
MEDEIROS CW de L e col. -
Rabdomiossarcoma primário de
diafragma: relato de caso e revisão
da literatura. Rev. Hosp. Clín. Fac.
Med. S. Paulo 57(2):67-72, 2002.
Os autores relatam um caso de
rabdomiossarcoma primário de dia-
fragma, uma apresentação extrema-
mente rara, com apenas 14 casos des-
critos na literatura mundial.
D.K., masculino, 18 anos, apresen-
tou 2 episódios de pneumotórax espon-
tâneo. Tomografia computadorizada e
ressonância magnética evidenciaram
massa em superfície diafragmática direi-
ta; após biópsia o diagnóstico foi com-
patível com rabdomiossarcoma embri-
onário tipo fusocelular, sendo realizada
pleuropneumonectomia direita devido à
presença de implante tumoral em pleura
visceral. Ele recebeu quimioterapia
adjuvante e se encontra livre de doença
15 meses após a cirurgia.
Os rabdomiossarcomas podem ser
divididos em quatro grupos cirúrgico-
patológicos, baseados nos critérios do
Intergroup Rhabdomyosarcoma Study
Group (IRSG) que levam em conside-
ração a extensão da doença e a deci-
são cirúrgica; no grupo I (como no
caso aqui relatado) os pacientes possu-
em doença localizada completamente
ressecada, apresentando o melhor
prognóstico.
O rabdomiossarcoma é um tumor
raro, podendo ter bom prognóstico
quando totalmente ressecado.
DESCRITORES: Rabdomiossar-
coma. Sarcoma. Diafragma. Embrio-
nário. Adolescente.
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